Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.33 |
| ▸ | RAF1 | P04049 | 13/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | CRHBP | P24387 | 2/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15498360 | 0.94 | MAPK14 (0.34) | KDM4EMAPK14RAF1MAPK13MAPK12 | |
| SCHEMBL326075 | 0.87 | RAF1 (0.35) | KDM4EMAPK14RAF1MAPK13MAPK12 | |
| SCHEMBL14645197 | 0.85 | RAF1 (0.35) | MAPK14RAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL324976 | 0.85 | TBK1 (0.37) | MAPK14RAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL937253 | 0.81 | RAF1 (0.32) | KDM4EMAPK14RAF1MAPK13MAPK12 | |
| SCHEMBL670419 | 0.81 | MAPK14 (0.34) | KDM4EMAPK14RAF1MAPK13MAPK12 | |
| SCHEMBL670420 | 0.81 | MAPK14 (0.34) | KDM4EMAPK14RAF1MAPK13MAPK12 | |
| SCHEMBL937254 | 0.81 | RAF1 (0.32) | KDM4EMAPK14RAF1MAPK13MAPK12 | |
| SCHEMBL15130800 | 0.81 | MAPK14 (0.34) | KDM4EMAPK14RAF1NPSR1CRHBP | |
| SCHEMBL15130678 | 0.81 | NR1I2 (0.33) | MAPK14RAF1NPSR1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | GOT1, RNASE1, SLC10A1 | KDM4E 4110/4885MAPK14 1892/4885RAF1 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.